Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:38 PM
Ignite Modification Date:
2025-12-24 @ 7:38 PM
NCT ID:
NCT00002003
Eligibility Criteria:
Inclusion Criteria
Patients must have the following:
* Positive HIV antibody, positive HIV culture or antigen capture, or prior diagnosis of AIDS by the CDC criteria.
* Diagnosis by pathological examination of large cell or immunoblastic lymphoma within measurable or evaluable disease.
* Pneumocystis carinii pneumonia (PCP) prophylaxis during the course of the study.
* Signed written informed consent.
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
* Acute intercurrent opportunistic infection, such as Pneumocystis carinii pneumonia (PCP) diagnosed within 3 weeks.
* Stage IE Central Nervous System lymphomas.
Patients with the following are excluded:
* More than one previous treatment for lymphoma.
* Acute intercurrent opportunistic infection, such as Pneumocystis carinii pneumonia (PCP) diagnosed within 3 weeks.
* Conditions that preclude obtaining an informed consent.
* Not accessible for scheduled treatment visits or follow-up.
* Stage IE Central Nervous System (CNS) lymphomas.
Prior Medication:
Excluded within 2 weeks of study entry:
* Zidovudine.
* Excluded:
* Doxorubicin dosing = or \> 300 mg/m2.
Prior Treatment:
Excluded:
* Received more than one previous treatment regimen for lymphoma.
Required:
* Prophylactic treatment for Pneumocystis carinii pneumonia (PCP) prophylaxis.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00002003
Study Brief:
Protocol Section:
NCT00002003